MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC
Ferdinandos Skoulidis(The University of Texas MD Anderson Cancer Center), Jack A. Roth(The University of Texas MD Anderson Cancer Center), Tyler F. Stewart(University of California San Diego), Hira Rizvi(Memorial Sloan Kettering Cancer Center), B. Carter(The University of Texas MD Anderson Cancer Center), Jonathan Killam(North Shore University Hospital), Laura Mezquita(Hospital Clínic de Barcelona), Collin M. Blakely(City College of San Francisco), Zenta Walther(Yale University), Sally C. M. Lau(University Health Network), Chad V. Pecot(University of North Carolina at Chapel Hill), Amy L. Cummings(University of California, Los Angeles), Hiram Shaish(Columbia University Irving Medical Center), John Madrigal(University of California, Los Angeles), Melina E. Marmarelis(University of Pennsylvania), Deepti Venkatraman(Dana-Farber Cancer Institute), Sarah B. Goldberg(Yale University), Matthew D. Hellmann(AstraZeneca (United States)), Biagio Ricciuti(Harvard University), Pradnya D. Patil(Cleveland Clinic), Kalatu Davies, Jonathan H. Goldman(University of California, Los Angeles), Christine M. Bestvina(University of Chicago Medicine Comprehensive Cancer Center), Adrian G. Sacher(Princess Margaret Cancer Centre), Kathryn C. Arbour(Memorial Sloan Kettering Cancer Center), Matthias Scheffler(TH Köln - University of Applied Sciences), Melanie Wain Kier(University of Pennsylvania), Fabrizio Tabbò(Ospedale San Pietro Fatebenefratelli), Mark G. Woodcock(Medical College of Wisconsin), B.I. Levy(Sidney Kimmel Cancer Center), Regan M. Memmott(The Ohio State University), Joseph C. Murray(Johns Hopkins University), Vincent K. Lam(Johns Hopkins University), Sharyn I. Katz(University of Pennsylvania), Lauren L. Ritterhouse(Brigham and Women's Hospital), Yasir Y. Elamin(The University of Texas MD Anderson Cancer Center), Anastasios Dimou(Mayo Clinic), Catherine A. Shu(Columbia University Irving Medical Center), Joseph T. Azok(Cleveland Clinic), Justin F. Gainor(Harvard University), Jonathan W. Riess(University of California Davis Medical Center), Mark M. Awad(Memorial Sloan Kettering Cancer Center), Ying Ni(Beijing Normal University), C. Liu(Memorial Sloan Kettering Cancer Center), Dwight H. Owen(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jeremy P. Segal(University of Chicago Medical Center), J. Zhang(The University of Texas MD Anderson Cancer Center), Ludovic Lacroix(Centre National de la Recherche Scientifique), R. Johnston, Jessica A. Hellyer(Montrose Center)
Cited by 3
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k